Cellectis
CLLS
#9407
Rank
โ‚ฌ0.13 B
Marketcap
1,32ย โ‚ฌ
Share price
-1.31%
Change (1 day)
-57.67%
Change (1 year)

Earnings for Cellectis (CLLS)

Earnings in 2026 (TTM): -โ‚ฌ57.71 Million

According to Cellectis's latest financial reports the company's current earnings are โ‚ฌ68.07 Million. In 2025 the company made an earning of -โ‚ฌ59.29 Million a decrease over its 2024 earnings that were of -โ‚ฌ32.05 Million. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Cellectis from 2015 to 2026

Annual earnings

Year Earnings Change
2026 (TTM) -โ‚ฌ57.71 Million-2.67%
2025 -โ‚ฌ59.29 Million85.03%
2024 -โ‚ฌ32.05 Million-73.42%
2023 -โ‚ฌ0.13 Billion60.8%
2022 -โ‚ฌ74.97 Million-31.26%
2021 -โ‚ฌ0.11 Billion27.21%
2020 -โ‚ฌ85.73 Million-14.62%
2019 -โ‚ฌ0.11 Billion30.34%
2018 -โ‚ฌ77.04 Million-15.02%
2017 -โ‚ฌ90.66 Million62.18%
2016 -โ‚ฌ55.9 Million185.48%
2015 -โ‚ฌ19.59 Million

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
Regeneron Pharmaceuticals
REGN
โ‚ฌ4.49 B-7,727.65%๐Ÿ‡บ๐Ÿ‡ธ USA
uniQure
QURE
-โ‚ฌ0.18 Billion 200.62%๐Ÿ‡ณ๐Ÿ‡ฑ Netherlands
Novavax
NVAX
-โ‚ฌ56.19 Million-4.66%๐Ÿ‡บ๐Ÿ‡ธ USA
Flexion Therapeutics
FLXN
-โ‚ฌ69.21 Million 17.42%๐Ÿ‡บ๐Ÿ‡ธ USA